Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer
Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.
Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care
Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.
Regeneron’s $2.2bn Parabilis pact signals rising interest in next-generation conjugates
ADCs changed cancer delivery. Regeneron and Parabilis now want Helicon peptides to push conjugates inside harder-to-drug biology.
Why Bayer’s HYRNUO first-line FDA review could reshape HER2-mutated NSCLC treatment sequencing
Bayer has FDA momentum in HER2-mutated lung cancer. The harder test is whether HYRNUO can move earlier without stronger survival data.
Genentech’s Tecentriq decision puts Natera’s Signatera at the centre of precision bladder cancer care
Bladder cancer treatment is becoming more selective. Tecentriq’s ctDNA-guided approval may redefine who gets adjuvant immunotherapy.
NUBEQA data at AUA 2026 sharpens Bayer’s mCSPC positioning against androgen receptor rivals
Bayer has stronger NUBEQA mCSPC data. The tougher test is whether clinicians view ARASEC as confirmatory or merely supportive.
ENHERTU enters curative-intent breast cancer care as FDA widens AstraZeneca and Daiichi Sankyo label
ENHERTU is moving earlier in breast cancer care. The bigger question is whether efficacy gains can outweigh ADC safety scrutiny.
AstraZeneca’s Imfinzi becomes first NHS immunotherapy for operable stomach cancer
Stomach cancer care gains immunotherapy, but NHS adoption now depends on surgery timing, toxicity management and recurrence data.
Why OnCusp Therapeutics’ CFO hire matters for its CDH6 antibody-drug conjugate strategy
CDH6 ADCs are heating up. OnCusp Therapeutics now needs capital discipline to turn CUSP06 promise into clinical and investor credibility.
Degron Therapeutics extends Series A as DEG6498 enters the harder phase of cancer drug validation
Molecular glue funding is back, but clinic data remain thin. Degron’s HuR bet now faces the proof burden in solid tumors.